nefazodone has been researched along with Depressive Disorder, Major in 42 studies
nefazodone: may be useful as an opiate adjunct
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the feasibility of screening and recruiting patients with major depression and congestive heart failure (CHF) in a tertiary care cardiology hospital and to obtain preliminary efficacy, tolerability, and safety data for nefazodone treatment of a major depressive episode in CHF patients." | 9.10 | An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. ( Calderone, A; Frasure-Smith, N; Lafontaine, S; Laliberté, MA; Lespérance, F; Rouleau, JL; Talajic, M; White, M, 2003) |
| "To evaluate the feasibility of screening and recruiting patients with major depression and congestive heart failure (CHF) in a tertiary care cardiology hospital and to obtain preliminary efficacy, tolerability, and safety data for nefazodone treatment of a major depressive episode in CHF patients." | 5.10 | An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. ( Calderone, A; Frasure-Smith, N; Lafontaine, S; Laliberté, MA; Lespérance, F; Rouleau, JL; Talajic, M; White, M, 2003) |
| " This double-blind study tested the efficacy of nefazodone versus placebo for the treatment of depression in actively drinking alcohol-dependent patients who were also participating in weekly group treatment for alcoholism." | 5.09 | Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. ( Blume, AW; Cowley, DS; Jaffe, C; Kingsley, E; Pages, KP; Ries, RK; Roy-Byrne, PP; Russo, JE, 2000) |
| "All patients suffered from major depressive disorder and had a score of at least 14 on the 17-item Hamilton Rating Scale (HAMD)." | 2.73 | Combination treatment for acute depression is superior only when psychotherapy is added to medication. ( Blom, MB; Dusseldorp, E; Haffmans, J; Hoencamp, E; Jonker, K; Spinhoven, P; van Dyck, R, 2007) |
| "Participants were 431 chronically depressed patients who received Cognitive Behavioral Analysis System of Psychotherapy (CBASP), alone (N=214) or in combination with nefazodone (N=217), as part of a randomized chronic depression study (Keller et al." | 2.71 | Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. ( Arnow, B; Blalock, JA; Blasey, C; Keller, MB; Klein, DN; Manber, R; Markowitz, JC; McCullough, JP; Riso, LP; Rothbaum, B; Rush, AJ; Thase, ME; Vivian, D, 2003) |
| "Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD." | 2.71 | Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. ( Arnow, B; Banks, P; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Howland, R; Keitner, GI; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Munsaka, M; Rothbaum, B; Rush, AJ; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J, 2003) |
| "Major depressive disorder is associated with considerable morbidity, disability, and risk for suicide." | 2.71 | Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. ( Dunner, DL; Heim, CM; Keitner, G; Keller, MB; Klein, DN; Kornstein, S; McCullough, JP; Nemeroff, CB; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Weiss, PM, 2003) |
| "Metyrapone treatment was well tolerated without serious adverse effects." | 2.71 | Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. ( Jahn, H; Kellner, M; Kiefer, F; Schick, M; Wiedemann, K; Yassouridis, A, 2004) |
| " The dosage of nefazodone was 100 to 600 mg/d; CBASP was provided twice weekly during weeks 1 through 4 and weekly thereafter." | 2.71 | Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. ( Arnow, BA; Banks, PL; Blalock, JA; Borian, FE; Howland, R; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Ninan, PT; Rothbaum, BO; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2005) |
| "Nefazodone was efficacious in symptom alleviation in patients with comorbid anxiety and depression." | 2.71 | Mixed anxiety and depression in older adults: clinical characteristics and management. ( Cassidy, EL; Lauderdale, S; Sheikh, JI, 2005) |
| "Data for 996 patients with major depressive disorder (DSM-III-R criteria), who participated in a 12-week acute phase study with nefazodone, were subjected to a post hoc analysis of changes in symptom cluster scores." | 2.71 | Symptom clusters as predictors of late response to antidepressant treatment. ( Grannemann, BD; Mahadi, S; Morris, DW; Trivedi, MH, 2005) |
| " Assessments included Clinical Global Impression Scales, Hamilton Rating Scales for Depression and Anxiety, Montgomery-Asberg Depression Rating Scale and the Patient Global Assessment Scale, in addition to a review of reported adverse events, vital sign measurements, electrocardiograms and clinical laboratory tests." | 2.70 | A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. ( Baldwin, DS; Hawley, CJ; Mellors, K, 2001) |
| "Patients with chronic forms of major depressive disorder were randomized to 12 weeks of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), or combined nefazodone/CBASP." | 2.70 | Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. ( Borian, FE; Crits-Christoph, P; Dunner, DL; Hirschfeld, RM; Keitner, G; Keller, MB; Klein, DN; Koran, LM; Kornstein, SG; Markowitz, JC; Miller, I; Nemeroff, CB; Ninan, PT; Rush, AJ; Schatzberg, AF; Thase, ME; Trivedi, MH, 2002) |
| "Major depressive disorder is one of the most common mental disorders in children and adolescents." | 2.53 | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016) |
| "Nefazodone was well tolerated and no significant changes in sexual function were reported." | 1.31 | Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. ( Beckham, JC; Davidson, JR; Feldman, ME; Hertzberg, MA; Moore, SD, 2002) |
| " Serial HRV recordings revealed that both the mean resting heart rate and systolic blood pressure significantly decreased after 21 days of nefazodone treatment (average dosage 413 mg/day), whereas after 10 days (average dosage 270." | 1.31 | Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone. ( Agelink, MW; Klieser, E; Linka, T; Majewski, T; Postert, T; Rotterdam, S; Wurthmann, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 35 (83.33) | 29.6817 |
| 2010's | 5 (11.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steidtmann, D | 1 |
| Manber, R | 12 |
| Blasey, C | 4 |
| Markowitz, JC | 12 |
| Klein, DN | 15 |
| Rothbaum, BO | 6 |
| Thase, ME | 15 |
| Kocsis, JH | 7 |
| Arnow, BA | 7 |
| Cipriani, A | 1 |
| Zhou, X | 1 |
| Del Giovane, C | 1 |
| Hetrick, SE | 1 |
| Qin, B | 1 |
| Whittington, C | 1 |
| Coghill, D | 1 |
| Zhang, Y | 1 |
| Hazell, P | 1 |
| Leucht, S | 1 |
| Cuijpers, P | 1 |
| Pu, J | 1 |
| Cohen, D | 1 |
| Ravindran, AV | 1 |
| Liu, Y | 1 |
| Michael, KD | 1 |
| Yang, L | 1 |
| Liu, L | 1 |
| Xie, P | 1 |
| Preskorn, SH | 1 |
| Kraemer, HC | 1 |
| Trivedi, MH | 8 |
| Rush, AJ | 11 |
| Gelenberg, AJ | 2 |
| Keller, ME | 1 |
| Leon, AC | 1 |
| Arnow, B | 5 |
| Maddux, RE | 1 |
| Riso, LP | 4 |
| Blalock, JA | 5 |
| Keitner, GI | 2 |
| Denton, WH | 1 |
| Carmody, TJ | 1 |
| Keller, MB | 9 |
| Stulz, N | 1 |
| Crits-Christoph, P | 2 |
| Blom, MB | 3 |
| Hoek, HW | 1 |
| Spinhoven, P | 3 |
| Hoencamp, E | 3 |
| Judith Haffmans, PM | 1 |
| van Dyck, R | 3 |
| Hertzberg, MA | 1 |
| Feldman, ME | 1 |
| Beckham, JC | 1 |
| Moore, SD | 1 |
| Davidson, JR | 1 |
| Amow, B | 1 |
| Klein, D | 1 |
| Korenstein, SG | 1 |
| Dunner, DL | 5 |
| Munsaka, M | 2 |
| Borian, FE | 6 |
| Keller, B | 1 |
| Vivian, D | 3 |
| McCullough, JP | 4 |
| Rothbaum, B | 3 |
| Argyropoulos, SV | 1 |
| Hicks, JA | 1 |
| Nash, JR | 1 |
| Bell, CJ | 1 |
| Rich, AS | 1 |
| Nutt, DJ | 1 |
| Wilson, SJ | 1 |
| Howland, R | 2 |
| Kornstein, SG | 4 |
| Hirschfeld, RM | 2 |
| Zajecka, J | 1 |
| Russell, JM | 1 |
| Miller, I | 3 |
| Banks, P | 1 |
| Nemeroff, CB | 2 |
| Heim, CM | 1 |
| Schatzberg, AF | 3 |
| Ninan, PT | 3 |
| Weiss, PM | 1 |
| Kornstein, S | 1 |
| Keitner, G | 3 |
| Schwartz, JE | 1 |
| Santiago, NJ | 1 |
| Vocisano, C | 1 |
| Castonguay, LG | 1 |
| Miller, IW | 1 |
| Lespérance, F | 1 |
| Frasure-Smith, N | 1 |
| Laliberté, MA | 1 |
| White, M | 1 |
| Lafontaine, S | 1 |
| Calderone, A | 1 |
| Talajic, M | 1 |
| Rouleau, JL | 1 |
| Tamam, L | 1 |
| Ozpoyraz, N | 1 |
| Mischoulon, D | 1 |
| Opitz, G | 1 |
| Kelly, K | 1 |
| Fava, M | 2 |
| Rosenbaum, JF | 1 |
| Hernandez-Avila, CA | 1 |
| Modesto-Lowe, V | 1 |
| Feinn, R | 1 |
| Kranzler, HR | 1 |
| Koran, LM | 2 |
| Jahn, H | 1 |
| Schick, M | 1 |
| Kiefer, F | 1 |
| Kellner, M | 1 |
| Yassouridis, A | 1 |
| Wiedemann, K | 1 |
| Almási, J | 1 |
| Rihmer, Z | 1 |
| Banks, PL | 1 |
| Cassidy, EL | 1 |
| Lauderdale, S | 1 |
| Sheikh, JI | 1 |
| Morris, DW | 1 |
| Grannemann, BD | 1 |
| Mahadi, S | 1 |
| Clayton, AH | 1 |
| Montejo, AL | 1 |
| Constantino, MJ | 1 |
| Papakostas, GI | 2 |
| Hoffman, T | 1 |
| Jonker, K | 2 |
| Haffmans, PM | 1 |
| Dusseldorp, E | 1 |
| Haffmans, J | 1 |
| Shelton, RC | 1 |
| Sajatovic, M | 1 |
| DiGiovanni, S | 1 |
| Fuller, M | 1 |
| Belton, J | 1 |
| DeVega, E | 1 |
| Marqua, S | 1 |
| Liebling, D | 1 |
| Roy-Byrne, PP | 1 |
| Pages, KP | 1 |
| Russo, JE | 1 |
| Jaffe, C | 1 |
| Blume, AW | 1 |
| Kingsley, E | 1 |
| Cowley, DS | 1 |
| Ries, RK | 1 |
| D'Mello, DA | 1 |
| Meland, R | 1 |
| Ransom, S | 1 |
| Agelink, MW | 1 |
| Majewski, T | 1 |
| Wurthmann, C | 1 |
| Postert, T | 1 |
| Linka, T | 1 |
| Rotterdam, S | 1 |
| Klieser, E | 1 |
| Sánchez-Lacay, JA | 1 |
| Lewis-Fernández, R | 1 |
| Goetz, D | 1 |
| Blanco, C | 1 |
| Salmán, E | 1 |
| Davies, S | 1 |
| Liebowitz, M | 1 |
| Jerome, L | 1 |
| Baldwin, DS | 1 |
| Hawley, CJ | 1 |
| Mellors, K | 1 |
| Gillin, JC | 1 |
| Smith-Vaniz, A | 1 |
| Schnierow, B | 1 |
| Rapaport, MH | 1 |
| Kelsoe, J | 1 |
| Raimo, E | 1 |
| Marler, MR | 1 |
| Goyette, LM | 1 |
| Stein, MB | 1 |
| Zisook, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| Partnership in Medication Management (PIMM): The Effects of One-on-one Medication Training on Medication Adherence in Patients With Mood Disorders[NCT02285608] | 166 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | |||
| Cognitive Behavioral Analysis System of Psychotherapy (CBASP) vs. Behavioral Activation (BA) in Persistently Depressed Treatment-resistant Inpatients: Efficacy, Moderators, and Mediators of Change[NCT04996433] | 396 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | |||
| Assessing the Emotional and Physiological Response of Adults to Completing a Self-report Scale on Exposure to Childhood Maltreatment - Online Component[NCT06152549] | 500 participants (Anticipated) | Observational | 2022-10-15 | Recruiting | |||
| Double-Blind, Placebo Controlled Trial of Metyrapone as Augmenting Agent in the Treatment of Major Depression[NCT00125554] | Phase 2 | 63 participants | Interventional | 1998-05-31 | Completed | ||
| Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.[NCT03491696] | Phase 4 | 14 participants (Anticipated) | Interventional | 2018-12-22 | Recruiting | ||
| Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529] | Phase 4 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for nefazodone and Depressive Disorder, Major
| Article | Year |
|---|---|
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; El | 2003 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 2004 |
Major depressive disorder, antidepressants, and sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 2006 |
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin | 2007 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Maj | 2008 |
29 trials available for nefazodone and Depressive Disorder, Major
| Article | Year |
|---|---|
Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression.
Topics: Adult; Antidepressive Agents; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Thera | 2013 |
Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2009 |
Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination.
Topics: Adaptation, Psychological; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cogniti | 2009 |
Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2010 |
Differential effects of treatments for chronic depression: a latent growth model reanalysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2010 |
Treatment of depression in patients from ethnic minority groups in the Netherlands.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Cross-Cultural Compariso | 2010 |
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Combined Modalit | 2003 |
Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2003 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; El | 2003 |
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; C | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disea | 2003 |
Therapeutic alliance in depression treatment: controlling for prior change and patient characteristics.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2003 |
Therapeutic reactance as a predictor of outcome in the treatment of chronic depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2003 |
An open-label study of nefazodone treatment of major depression in patients with congestive heart failure.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnostic and St | 2003 |
Nefazodone treatment of comorbid alcohol dependence and major depression.
Topics: Adult; Alcoholism; Analysis of Variance; Chi-Square Distribution; Depressive Disorder, Major; Diagno | 2004 |
Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavi | 2003 |
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Cortodoxone; Dehydroepiandrosterone; Depr | 2004 |
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Cortodoxone; Dehydroepiandrosterone; Depr | 2004 |
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Cortodoxone; Dehydroepiandrosterone; Depr | 2004 |
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Topics: Adrenocorticotropic Hormone; Adult; Antidepressive Agents; Cortodoxone; Dehydroepiandrosterone; Depr | 2004 |
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Cros | 2005 |
Mixed anxiety and depression in older adults: clinical characteristics and management.
Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Di | 2005 |
Symptom clusters as predictors of late response to antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnostic and Statisti | 2005 |
Dropouts versus completers among chronically depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorder | 2007 |
Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder | 2007 |
Combination treatment for acute depression is superior only when psychotherapy is added to medication.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressiv | 2007 |
Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder, Major; Fema | 1999 |
Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modality Therapy; | 2000 |
Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Hispanic or Lat | 2001 |
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Long | 2001 |
An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder.
Topics: Arousal; Combat Disorders; Depressive Disorder, Major; Dreams; Electroencephalography; Humans; Male; | 2001 |
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Comb | 2002 |
8 other studies available for nefazodone and Depressive Disorder, Major
| Article | Year |
|---|---|
How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Asthma; Broncho | 2008 |
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Chronic Disease; Cognitive Behavi | 2008 |
Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Chronic Disease; Clinical Trials as Topic; C | 2002 |
Discontinuation symptoms associated with nefazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relations | 2003 |
A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relations | 2004 |
Nefazodone and hypotension: complication or coincidence.
Topics: Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Depressive Disorder, Major; Female; | 1997 |
Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Pressure; Case-Control Studies; Depress | 2001 |
Bupropion and drug-induced parkinsonism.
Topics: Bupropion; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Humans; Male; M | 2001 |